Physician profile
Anna C Newcombe
NPI 1508806662
$2,506.32
in general payments reported to CMS, 2019-2025
9 companies · $839 in 2025
The $839 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $247 · 2023: $405 · 2024: $880 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $813.06 | 2023-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $424.13 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.28 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $264.81 | 2023-2025 | Spravato |
| Novo Nordisk INC | $218.97 | 2021-2022 | |
| Glaxosmithkline, LLC. | $122.95 | 2024 | Arexvy |
| Corcept Therapeutics | $119.69 | 2025 | Korlym |
| Alkermes, INC. | $119.36 | 2025 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $102.07 | 2021-2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Newcombe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.